Background: Herpesviruses are widespread viruses, causing severe infections in both humans and animals. Eradication of herpesviruses is extremely difficult because of their ability to establish latent and life-long infections. However, latency is only one tool that has evolved in herpesviruses to successfully infect their hosts; such viruses display a wide (and still incompletely known) panoply of genes and proteins that are able to counteract immune responses of their hosts. Envelope glycoproteins and cytokine inhibitors are two examples of such weapons. All of these factors make it difficult to develop diagnostics and vaccines, unless they are based on molecular techniques. Materials and Methods: Animal herpesviruses, because of their striking similarity to human ones, are suitable models to study the molecular biology of herpesviruses and develop strategies aimed at designing
Introduction
Herpesviruses have recently become a major subject in virology. They cause widespread infections whose main feature is the establishment of latency. This trait makes it very difficult to eradicate herpesviruses, because no therapies or vaccines have been proved to be fully effective against them. Animal herpesviruses may serve as a valuable model to investigate the immune response of host organisms as well as to design and assay new vaccines against these infectious agents. Vaccine development has been widely investigated in the bovine herpesvirus 1 (BHV-1) model, giving rise to a wide number of publications on the subject. Such a model should be very informative for other herpesviruses-caused diseases, including human ones.
BHV-1 is the causative agent of infectious bovine rhinotracheitis (IBR) (1) (2) (3) (4) ], Southern hybridization, and mapping studies (5); traditional methods rely on serological tests (6) and viral antigen characterization. Each herpesvirus isolate can contain many different strains, each being distinguishable from each other by sequencebased methods (7); e.g., Cooper and Los Angeles (LA) are the most common BHV-1 strains in Europe and the United States, respectively (8) .
Pathogenesis and Clinical Features
Clinical steps in the pathogenesis of herpesvirus infections are acute disease, latency, and reactivation. Such viruses are transmitted directly by aerosol or by close contact among infected animals. Indirect transmission may occur via contaminated food or water, or semen for artificial insemination. The potential portals of entry are the nasal cavity, oropharynx, eyes, and genital tract. Normally, the first round of viral replication takes place in the epithelial cells at the portal of entry. The symptoms of the acute disease restricted to local areas (the upper respiratory tract and eyes) are mainly associated with destruction of infected epithelial cells caused by virus replication. The highest virus titers are produced and excreted at this stage of infection. These infections are usually self-limiting, thanks to a prompt immune response, and recovery usually takes place within 1 to 2 weeks. Local lesions, however, may facilitate secondary bacterial infections, causing more severe damage, such as pneumonia.
The virus may spread in the infected host by viremia, gaining access to a broader range of tissues and organs and causing a variety of diseases-e.g., abortion and enteritis are the most serious consequences of BHV-1 infections. Furthermore, the virus can enter nervous cells, establishing a latent infection in sensitive ganglia. It is not yet clear whether the infection of the central nervous system (CNS) by herpesviruses is achieved via axonal transport (during its initial replication at the portal of entry, the herpesvirus may enter the axons of local nerve cells) or via viremic spread (9) .
Clinical symptoms of infection with herpesviruses are characterized by a large variability in severity: they may be mild and localized or they may include severe generalized illness, leading in some cases to death or, in contrast, going unnoticed. The pathology of BHV-1 -caused diseases is largely due to respiratory infection; after a primary infection, virus replicates in epithelial cells of the high respiratory tract, causing necrosis. In some cases, BHV-1 can propagate itself in the organism by a systemic route or to the lungs, inducing a bronchopneumonia often complicated by secondary bacterial superinfections (10) . During primary infection, when virus is replicating intensively, a large amount of viral particles is present in nasal exudates; the infected animals are highly contagious to others in their surroundings.
In cattle, clinical symptoms of the respiratory disease are the following: after 2 to 6 days, pyrexia, reduced appetite (anorexia), dyspnoea (increased respiratory rate), cough, bilateral nasal discharge, and depression occur, often accompanied by conjunctivitis and mucopurulent ocular secretions. Auscultation reveals the presence of a tracheitis. Animals recover within 2 weeks, except when bacterial superinfection occurs (in approximately 10% of the affected animals). In this case, bronchopneumonia can cause death.
Infections of the genital tract are frequently caused by artificial insemination practice. The minimal dose to infect a cow by artificial insemination has been estimated to be 32 infectious viral particles. In males, preputial and penile mucosae seem to be the tissues of the male genital tract supporting BHV-1 replication (11) . Clinical signs vary from mild to severe balanoposthitis and may be associated with a decrease in semen quality (reduced motility and morphological abnormalities of sperm cells) (12) . Because semen is usually contaminated with virus from preputial and penile mucosae, seminal plasma rather than sperm cells contains the virus.
In females, infection may lead to infertility disturbances, mainly endometritis (13) . The risk of transmitting BHV-1 to inseminated cows by using BHV-1-seropositive bulls for artificial insemination is substantially reduced by preadsorption of semen (14) and by testing semen batches. When IBR develops in a herd that includes pregnant cattle, abortions may occur after 3 to 6 weeks post infection, mainly between the 5th and 8th month of pregnancy. Under field conditions, about 25% of pregnant cattle undergo abortion after an outbreak of IBR (15) .
Calves can also become infected at and after birth. Cows suffering from acute infection can infect newborns directly in the uterus, through a systemic route, or via contaminated nasal secretions. Parturition is associated with increased blood levels of glucocorticoids; also, labor constitutes a stress in and of itself, adding to the endocrine status. Physiologically, parturition represents a risk situation that might result in bovine rhinotracheitis virus reactivation and/or, re-excretion. It is well established that latent IBRcausing virus can undergo reactivation by both stressing conditions or administration of glucocorticoids (16).
Epidemiology and Diagnosis
Epidemiology IBR is considered a species-specific cattle disease. Other animal herpesviruses, strictly related to BHV-1, cause similar diseases in pigs, goats, minks, and ferrets. Human herpesviruses are responsible for systemic, eye, and genital infections, in both children and adults. Some herpesviruses have been related to tumor onset, e.g., Burkitt's lymphoma, and nose-pharyngeal carcinoma.
BHV-1 comes in contact with herds mainly through introduction of new animals, either in the acute phase of a primary disease or when latently infected. As illustrated in Figure 1 , even semen from infected bulls and infected embryos are suitable viral carriers. Once the virus enters a herd, it is mainly spread by direct contact between animals (through respiratory, ocular, or genital secretions). An indirect route of spread is also possible, by means of contaminated instruments. Since Switzerland and Denmark succeeded in BHV-1 eradication, attention has been focused on virus eradication in the other EC countries. Presently, a number of countries have entered eradication programs. In the countries where BHV-1 infection has a high prevalence, eradication is only economically feasible by preventing new infections while increasing the culling of infected animals. Awareness of epidemiological risks and improvement of management both play an important role in limiting or even avoiding viral spread within and between herds (17) . A hallmark of the herpesvirus biological cycle is its ability to establish latent, life-lasting, and periodically reactivating infections in the host. It is the most harmful herpesvirus property, which makes the use of semen from BHV-1-seropositive bulls or embryos a major concern. Bulls, once infected, must be regarded as lifelong potential BHV-1 sources. In fact, BHV-1 spreads along the nerves to the sympathetic ganglia, where it remains latent for life (11) , until a proper stimulus induces its reactivation (18) . Several conditions that are common in livestock breeding are quite stressful, making cattle prone to bacterial and viral infections as well as to herpesviruses reactivation. These include increased levels of corticosteroids, pregnancy, transport, entrance into a new herd, concomitant viral or bacterial infections, poor management conditions, and deficient diet.
In bovine species, transport of the virus is associated with an increase in corticoid blood level; thus virus-carrying animals are simultaneously submitted to stressful conditions. Transport is indeed responsible for reactivation of IBR virus. BHV-1 re-excretion and rise in neutralizing antibodies are direct and identifiable indicators of reactivation (19) .
Other stressful situations may play an important role in BHV-1 infection of cattle-e.g., coinfection with other pathogens, such as bovine immunodeficiency-like virus (BIV) (20). Inadequate diet and mineral deficiency may also affect acutephase reactivation of BHV-1 infection (21).
Much of the dynamics of BHV-1 infection, however, is unclear-i.e., how long BHV-1 can circulate in a herd, whether all susceptible animals become infected, or whether circulating BHV-1 is present after all the animals have seroconverted. Knowledge of transmission parameters and population dynamics of BHV-1 under field conditions can give information pertinent to the prevention of viral persistence, avoidance of virus spread, eradication of virus, and protection for the target population (22 Table 1 .
Herpesvirus glycoproteins (gI, gII, and gIV) are involved in several steps of viral replication: they are responsible for the initial attachment of the virus to the cellular receptor and the subsequent penetration of the host cell; they account for the tropism of the virus for tissues and organs; and they are involved in envelopment of the capsid, viral egress and transmission of infection by cell-to-cell spread (50-52). Some glycoproteins are receptors for the Fc fraction of immunoglobulins-e.g., gI and gE are predicted to form a Fc receptor, whereas gC has been shown to bind complement factor C3b (49,53). The initial attachment of herpesviruses to permissive cells is mediated by an interaction of gIII molecules with cellular glycosaminoglycan heparinsulfate through heparin-like receptors (54).
Recently, the existence of multiple alphaherpesvirus co-receptors that interact Glycoproteins, which are mainly expressed on the virus envelope, share a remarkable degree of structural and functional conservation in many herpesviruses, including some that are only distantly related (70,73). The architecture of many genomic regions is strictly conserved within herpesviruses, while similarity varies characteristically from gene to gene (74) .
Molecular virology of BHV-1 and other herpesviruses has advanced considerably in the last few years, propelled by genome projects and by inquiries into the functions of key viral proteins. Thanks to international cooperation, the nucleotide sequences of many herpesviruses are now known or close to being completely determined (49).
Lytic Cycle
Northern blot analysis shows that herpesvirus genes are transcribed and expressed in a cascade, and are temporally and spatially regulated (75) . As shown in Figure 2 During latent infection of neurons, gene expression is strictly limited (Fig. 3) (93, 97, 98 Cell-mediated immune response is first detected about 5 days postinfection (pi) and takes place at approximately 8 to 10 days pi. Infection induces neutralizing antibodies capable of preventing attachment and penetration; these antibodies can also take part in antibody-mediated complement lysis of infected cells or in antibodydependent cell cytotoxicity. Neutralizing antibodies, mainly IgM, followed by IgG, are usually detected around 10 days after infection. Mucosal immunity also becomes activated, as shown by IgA found in nasal and genital secretions. The virus also induces specific cellular responses including induction of cytokines, which either directly or indirectly inhibit virus replication by activation of effector cells (104) . Lymphocytes, NK-like cells, macrophages, and polymorphonuclear neutrophils can kill virus-infected cells either directly, via MHC-I recognition, or by interacting with antibody to induce cell death by antibody-dependent cell cytotoxicity (105) . Killing of virus-infected cells occurs after the expression of viral antigens on the surface of infected cells (106) .
The relation between the timing of cell killing and completion of virus assembly explains whether the cycle of infection is aborted or productive viral replication occurs. Indeed, any enhancement of viral killing dramatically reduces viral load. The role of antibody is critical in preventing infection and viral spread. Conversely, cell-mediated immunity may help recovery from infection. In most cases the peak activity of these cellular responses occurs at 7-10 days pi (107) . The role of most viral proteins is not presently known, except for that of the major glycoproteins, which act as targets for cell-mediated im-munity (cell interaction and lysis by NK cells) (106) (110) . This is a sort of selective removal of viral antigenassociated antigen-presenting cells (APCs). In acute viral infection BHV-1 can induce apoptosis simply through attachment of the viral particles to target cells (111) . Therefore, CTLs serve as a major immune mechanism against BHV-1 infection as well as selective eliminators of infected cells (110) .
BHV-1 and Cytokines
Cytokines are physiologically important immunomodulators that are produced by many different cell types and that exert broad pleiotropic effects. Many of these effects are important in host defense mechanisms against viral infections. Even without complete bovine gene maps, those developed thus far have been used to identify genetic markers that are associated with increased zootechnics production or enhanced disease resistance and that can be manipulated in selective breeding programs. This type of study makes it possible to correlate, for instance, a specific interferon (IFN) genotype and the severity of clinical development following herpesvirus infection (1 12).
IFN-y plays an important role in the generation of non-MHC-restricted cytotoxic responses of cattle to BHV-1, which represents the most apparent cellular-mediated immune response during BHV-1 infection (105). More recent studies on the role of IFN-y in host immunity to other herpesviruses revisited the issue of IFN-'y's essential participation in the control of infection. IFN-y seems to be required to contain the initial infection, but the functions mediated by T cells appear to proceed effectively even in the absence of IFN-y (113). The conclusion is that IFN-y, by enhancing T cell-mediated clearance mechanisms, might be a critical mediator of immunity to herpesvirus. IFN--y should be considered in terms of the major and compensatory mechanisms available to the body to effect immunity to viral infection (114) . Some herpesviruses (e.g., HHV-8) were recently shown to express a protein hampering IFN-,y actions. Such a discovery will shed new light on molecular mechanisms that intimately regulate virus-host interactions. (125) . Other IBRVs carry genes coding for "late" glycoprotein and "early" enzymes of porcine pseudorabies virus (126, 127) . Bacterial genes have also been successfully expressed in BHV-1, e.g., Escherichia coli lacZ gene (54).
BHV-1 vector has proven its effectiveness in delivering foreign products (e.g., antigens) to mucosal surfaces of the respiratory tract (54). Moreover, BHV-1, being a neurotropic virus like HSV-1, is also considered a suitable candidate for neuronal gene delivery.
Prophylaxis: Vaccines and Eradication
IBR-free countries have achieved this status by applying diagnostic and slaughtering programs for serologically positive animals. Such a method works well where an infection shows a low prevalence (128) . In countries with high infection rates, however, diagnosis-and-eradication procedures would cause large financial losses. Here the best way to eradicate infection is based on combined vaccination-eradication programs. Indeed, vaccination is the most cost-effective measure to prevent and limit infections. The primary aim in using BHV-1 vaccines is to reduce signs of disease and thereby the economic impact of BHV-1 infections. Currently available vaccines do not prevent the establishment of BHV-1 in a latent state. It is not known whether passive immunity can prevent viral excretion and latency after primary infection. However, passive immunity acquired from colostrum was proved to protect newborn calves against the fatal multisystemic diseases caused by BHV-1 infection (129). Maternal antibodies do not prevent initial viral replication, allowing onset of latency. Once maternal antibodies get lost, animals likely become seronegative carriers of latent virus, since seroconversion or reactivation can take place. IBR control programs should therefore take into account the existence of latently infected seronegative animals (130 (142) , reactivation of latent vaccine strain (143), enhancement of keratoconjunctivitis (144) and abortion (145) , and ovarian lesions (146, 147) . In addition, BHV-1 vaccines have been found on occasion to be contaminated (148) . Killed vaccines may induce local tissue reactions or abscess and hypersensitivity reactions (131) .
Engineered Subunit Vaccines
In order to develop effective strategies of subunit immunization, it is important to recognize the role of major glycoproteins both in inducing antibody and in stimulating cell-mediated response. Since BHV-1, like other viruses, enters cells by interacting with host cell receptors, a convenient point of intervention is to counteract interactions between host cells and viral surface glycoproteins. BHV-1 glycoproteins gI, gIII, and gIV are involved in attachment to host cells and in virus entry. Animals immunized against gI, gIll, and gIV produce neutralizing antibodies able to block virus infectivity in vitro and even significantly limit virus replication in vivo (149) . Major BHV-1 glycoproteins are known immunodominant antigens (150, 151) : bovine immune responses are addressed to gI (homologous to HSV-1 gB), glll (homologous to HSV-1 gC), and gIV (homologous to HSV-1 gD) (152) (153) (154) (155) .
A second target for vaccines is proteins eliciting cytotoxic responses. These are targeted by cytotoxic T cells, which lyse virus-infected cells before the virus carries out its replicative cycle, thus reducing the overall virus load and clinical disease. The IE proteins of herpesviruses are pri-273 mary targets of CTLs (1 56). Efficient genetically engineered vaccines should induce the production of antibodies or stimulate cytotoxic T cells directed against early surface glycoproteins expressed on host cells long before infectious viral particles are released; this should be more effective than mere killing of intact virus or virusbudding infected cells. gI and gIV glycoproteins, early expressed after cell infection and long before BHV-1 is released from virus-infected cells, were shown fit to immunize cattle (61).
Subunit vaccines are safer than live ones, being made of recombinant viral antigens. However, all such vaccines need adjuvants to evoke a stronger and effective immune response. The search for better adjuvants has brought about an evaluation of the role of cytokines in such vaccines: the immune response to subunit vaccines is enhanced when IL-2 or IL-1iB are added to common adjuvants (118, 120) .
Major viral proteins involved in infection and replication have been produced in various expression systems (157) (158) (159) . Challenge of animals vaccinated with recombinant gIV produced in different expression systems (E. coli, vaccinia virus, adenovirus, baculovirus, and mammalian cells) showed that all proteins were immunogenic, but not all raised neutralizing antibodies in vaccinated hosts, thus blocking onset of clinical symptoms and virus shedding. For example, E. coli produced recombinant gIV was immunogenic, but homologous proteins from mammalian and insect cells showed a better capacity for inducing neutralizing antibody and reducing viral shedding (160) (161) (162) .
In some cases, immunogenicity of single antigens or subunits can be improved by rebuilding a whole particle through addition of phospholipids, cholesterol, or steroid adjuvants such as Quil A. BHV-1 antigens induced strong immunity when administered as liposomes or through immunostimulating complexes (ISCOMS) technology (163) . Virus-like particles expressing varicella zoster virus (VZV) antigens have also been shown to induce protective immunity in mice (164) . Timing and controlled release of antigens may also help to establish an effective immunity in the host (163, 165, 166) .
Modified Live Vaccines
Recent advances in our understanding of specific virulence genes of BHV-1 and other herpesviruses have made possible the specific deletion of genes to accomplish genetic attenuation of viral strains (167) . Some structural genes (e.g., gIII, gE) and some genes involved in nucleic acid metabolism (e.g., tk gene) can be deleted without significantly affecting viral replication in vitro. This opens the way to the development of BHV-1 strains carrying specific deletions (168) (169) (170) (171) (172) .
The deletion of tk, a gene involved in nucleic acid metabolism, or the ablation of sequences coding for glycoprotein genes (e.g., gC or gE) caused a dramatic change in virulence of BHV-1 in vivo (Fig. 4) . This approach also allowed development of diagnostic in vitro tests to differentiate vaccinated animals from seronegative latent carriers (154, 155, 173) . Through this strategy marker vaccines have been developed, i.e., vaccines based on single or multiple deletion of inessential genes, allowing discrimination between vaccinated and naturally infected animals through their antibody responses. In other words, vaccinated animals lack antibodies against a strongly immunogenic but unprotective viral protein that evokes immune responses in hosts following natural infection with field viral strains. Such marker protein is not expressed in vaccine viruses, allowing a suitable immunoscreening procedure to be set up and carried out. Hence, a marker vaccine, used in conjunction with suitable serological tests, enables use of diagnosis-and-eradication strategies in highly infected herds, because vaccination cannot be misled with natural infection, significantly reducing viral transmission rate. Additional advantages of marker vaccines are (1) the seroepidemiology of infections can be studied in a vaccinated population; (2) the use of vaccines no longer interferes with serological diagnosis on a herd or individual level; and (3) the efficacy of vaccines can be well evaluated under field conditions (20,56,174). Modified-live BHV-1 virus mutants, irreversibly attenuated by deletions in tk gene and marker genes, e.g., gE, provide safe, efficacious, and rationally designed vaccines. In conjunction with sensitive and specific differential ELISA diagnostic tests, these latter vaccines enable veterinarians to distinguish vaccinated animals from those infected with field strains (175) .
A tk-deficient, gC-deleted, mutant BHV-1 protected cattle against IBR and reduced viral shedding upon challenge (176) . Calves inoculated with genetically engineered gG-or gE-deleted mutant strains were better protected against challenge than those given a gI or gI/gE double-deleted mutant virus (168) . Although gE-negative BHV-1 can establish latency in trigeminal ganglia (103) 
Conclusions and Perspectives
BHV-1 may serve as a general model for a better understanding of herpesvirus infections in natural hosts and may also be of value as a model for herpesvirus-caused diseases, which are also important for humans. The increasing literature dealing with BHV-1 provides proof of economic and scientific importance of herpesviruses today.
Herpesviruses survive in nature thanks to a double-track strategy. During primary infection, viral dissemination within susceptible populations raises a strong immune response and in most cases the population does not display infection-associated diseases creating a long-term reservoir (latent virus) that becomes meaningful upon reactivation. Then, apparently healthy animals are able to reexcrete and transmit the virus to nonimmune and immune hosts. Herpesviruses have an efficient machinery for making this strategy effective. A set of essential genes is able to produce a high titer of infectious particles during primary infection and reactivation. A second set of nonessential and conditional-essential genes are required to establish latency, reactivation, virulence, and modulation of the host's immune response. In recent years, wide breakthroughs have led to the discovery of the BHV-1 life cycle; however, its efficiency in infecting and replicating depends not only on viral but also on the host's factors (9) .
Efficacy and safety are the main criteria for assessing the quality of vaccines (185) . The efficacy of vaccines is primarily assessed by a vaccination-challenge experiment in the target host (bovine). Subsequently, the vaccine's ability to reduce virus transmission is evaluated and evaluation of the vaccine's effectiveness is finalized in a field trial. Safety of BHV-1 vaccines is assessed by a series of experiments, usually with a 10-fold dose of vaccine in field trials (133) . The effect of spreading capacity in cattle population, infection of non-target animals, and reversion to virulence are also tested (186) .
The precise mechanisms underlying induction and maintenance of protective immunity after vaccination are far from being clearly understood. Protective immunity consists of immunity against fever, development of nasal lesions, other signs of disease, viral replication, viral shedding, or against infection. These criteria of immunity are based on different immunological processes. The elucidation of immunological mechanisms underlying the protective immunity should lead to the development of more effective BHV-1 vaccines. A better understanding of the pathogenesis of BHV-1 will also certainly contribute to a more rapid development of novel vaccines. Since only the first generation of marker vaccines has been developed recently, there is room for improving the efficacy of vaccines.
Although no completely efficacious vaccines are available against BHV-1 and other herpesviruses, more insight into the mechanisms of immunity should be stimulated. Advances in identification of different lymphocyte subsets in cattle, more insight into the complex interaction between the different immune cells with each other and the target, beginning elucidation of the roles of cytokines, and increasing emphasis on the development of more efficient adjuvants and delivery systems promise a better understanding of how to stimulate a protective immune response in vaccinated animals (187 
